What is the recommended management for restless legs syndrome?

Management of Restless Legs Syndrome

For adults with RLS, initiate treatment with gabapentinoids (gabapentin enacarbil, gabapentin, or pregabalin) as first-line pharmacologic therapy, and address iron deficiency with IV ferric carboxymaltose or oral ferrous sulfate when ferritin ≤100 ng/mL or transferrin saturation <20%. 1

First-Line Pharmacologic Treatment

The 2025 American Academy of Sleep Medicine guidelines represent a major shift from previous recommendations, now establishing strong recommendations for three gabapentinoid agents:

• Gabapentin enacarbil (strong recommendation, moderate certainty) 1
• Gabapentin (strong recommendation, moderate certainty) 1
• Pregabalin (strong recommendation, moderate certainty) 1

These agents achieve approximately 70% response rates (much or very much improved symptoms) compared to 40% with placebo, and critically avoid the augmentation risk that plagues dopaminergic therapy. 2

Iron Repletion Strategy

Iron supplementation is essential before or concurrent with pharmacologic therapy:

• IV ferric carboxymaltose 1000 mg receives a strong recommendation for patients with appropriate iron status 1
• Oral ferrous sulfate 325-650 mg daily or every other day is suggested when ferritin ≤100 ng/mL or transferrin saturation <20% 1, 2
• IV low molecular weight iron dextran and IV ferumoxytol are conditional alternatives 1

The threshold for iron supplementation has evolved—treatment should be considered even with "low-normal" iron indices (ferritin ≤100 ng/mL), not just frank deficiency. 2

Dopamine Agonists: Now Second-Line with Major Caveats

The AASM now suggests AGAINST standard use of all dopamine agonists due to augmentation risk (7-10% annual incidence):

• Pramipexole - conditional recommendation against standard use 1
• Ropinirole - conditional recommendation against standard use 1
• Transdermal rotigotine - conditional recommendation against standard use 1
• Levodopa - conditional recommendation against standard use 1

These may only be considered for short-term use in patients who prioritize immediate symptom reduction over long-term augmentation risk. 1 This represents a dramatic departure from older guidelines that positioned dopamine agonists as first-line therapy. 3, 4

Cabergoline receives a strong recommendation AGAINST use due to cardiac valvulopathy risk. 1

Additional Pharmacologic Options

For patients requiring alternatives or add-on therapy:

• Extended-release oxycodone and other opioids - conditional recommendation, particularly valuable for refractory or augmented RLS 1
• Dipyridamole - conditional recommendation 1

Low-dose opioids (methadone 5-10 mg daily) often benefit patients who fail first-line treatment or have augmented RLS. 2

Medications to Avoid

Actively discontinue exacerbating medications when possible:

• Serotonergic antidepressants 2
• Dopamine antagonists 2
• Centrally acting H1 antihistamines (e.g., diphenhydramine) 2
• Bupropion - conditional recommendation against use 1
• Carbamazepine - conditional recommendation against use 1
• Clonazepam - conditional recommendation against use 1
• Valproic acid - conditional recommendation against use 1

Non-Pharmacologic Approaches

Conditional recommendations support:

• Bilateral high-frequency peroneal nerve stimulation (conditional recommendation, moderate certainty) 1

Mental alerting activities and avoidance of symptom triggers should be implemented, though these lack strong evidence. 5

Special Population: End-Stage Renal Disease

For RLS with ESRD, the approach differs:

• Gabapentin - conditional recommendation 1
• IV iron sucrose when ferritin <200 ng/mL and transferrin saturation <20% (conditional recommendation) 1
• Vitamin C - conditional recommendation 1

Pediatric RLS

For children with RLS:

• Ferrous sulfate with appropriate iron status (conditional recommendation, very low certainty) 1

Critical Clinical Pitfalls

Augmentation recognition is essential: This iatrogenic worsening manifests as increasing symptom severity, earlier onset during the day, and anatomic spread beyond the legs. 6, 7 If augmentation occurs with dopamine agonists, switch to gabapentinoids or opioids rather than increasing the dopaminergic dose. 6, 7

Iron status must be checked: Even "normal" ferritin (50-75 ng/mL) may be insufficient for RLS patients—aim for ferritin >100 ng/mL. 2, 5

Avoid polypharmacy traps: Do not add antihistamines for sleep or SSRIs for comorbid depression without considering RLS exacerbation. 2

Treatment Algorithm

1. Assess and correct iron deficiency (ferritin ≤100 ng/mL or transferrin saturation <20%) 1, 2
2. Discontinue exacerbating medications (antidepressants, antihistamines, dopamine antagonists) 2
3. Initiate gabapentinoid therapy (gabapentin enacarbil, gabapentin, or pregabalin) 1
4. If inadequate response or intolerance: Consider opioids (extended-release oxycodone) rather than dopamine agonists 1, 2
5. Reserve dopamine agonists only for short-term use when patients explicitly accept augmentation risk 1

The 2025 AASM guidelines fundamentally reorient RLS management away from dopaminergic therapy toward gabapentinoids and iron optimization, reflecting growing recognition of augmentation's devastating long-term impact on quality of life. 1, 2